Scholarlink

<p>This study aimed to assess the clinical utility of serum interferon-lambda 3 (IFN-λ3) as a sequential biomarker for treatment response and disease control in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM)-associated interstitial lung disease (ILD). Serum IFN-λ3 levels were measured in 24 patients with anti-MDA5 antibody-positive DM-ILD at diagnosis and 1&#xa0;month after initiating immunosuppressive therapy. Patients were categorized into two groups based on clinical outcomes: a good control group (<i>n</i> = 16; survived without relapse for ≥ 1&#xa0;year) and a poor control group (<i>n</i> = 8; died from ILD progression or relapse within 1&#xa0;year). Changes in serum IFN-λ3 levels and differences between groups were analyzed. In the good control group, serum IFN-λ3 levels significantly decreased from 94.6 to 12.7&#xa0;pg/mL (<i>p</i> &lt; 0.001), whereas no significant change was observed in the poor control group (129.0 to 118.8&#xa0;pg/mL). Furthermore, serum IFN-λ3 levels at 1&#xa0;month were significantly lower in the good control group than in the poor control group (<i>p</i> = 0.004). Serum IFN-λ3 levels may reflect short-term treatment response and could serve as a useful sequential biomarker for assessing disease control in patients with anti-MDA5 antibody-positive DM-ILD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月24日

查看全文
  • Yoshihiro Kitahara,
  • Tomoyuki Fujisawa,
  • Atsuki Fukada,
  • Keigo Koda,
  • Taisuke Akamatsu,
  • Masaki Ikeda,
  • Masato Fujii,
  • Mitsuru Niwa,
  • Yusuke Kaida,
  • Hiroyuki Matsuda,
  • Koshi Yokomura,
  • Naoki Koshimizu,
  • Mikio Toyoshima,
  • Shiro Imokawa,
  • Dai Hashimoto,
  • Keita Yamashita,
  • Moriya Iwaizumi,
  • Masato Maekawa,
  • Yusuke Inoue,
  • Hideki Yasui,
  • Hironao Hozumi,
  • Yuzo Suzuki,
  • Masato Karayama,
  • Kazuki Furuhashi,
  • Noriyuki Enomoto,
  • Naoki Inui,
  • Takafumi Suda

摘要

This study aimed to assess the clinical utility of serum interferon-lambda 3 (IFN-λ3) as a sequential biomarker for treatment response and disease control in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM)-associated interstitial lung disease (ILD). Serum IFN-λ3 levels were measured in 24 patients with anti-MDA5 antibody-positive DM-ILD at diagnosis and 1 month after initiating immunosuppressive therapy. Patients were categorized into two groups based on clinical outcomes: a good control group (n = 16; survived without relapse for ≥ 1 year) and a poor control group (n = 8; died from ILD progression or relapse within 1 year). Changes in serum IFN-λ3 levels and differences between groups were analyzed. In the good control group, serum IFN-λ3 levels significantly decreased from 94.6 to 12.7 pg/mL (p < 0.001), whereas no significant change was observed in the poor control group (129.0 to 118.8 pg/mL). Furthermore, serum IFN-λ3 levels at 1 month were significantly lower in the good control group than in the poor control group (p = 0.004). Serum IFN-λ3 levels may reflect short-term treatment response and could serve as a useful sequential biomarker for assessing disease control in patients with anti-MDA5 antibody-positive DM-ILD.